cardiovascular
diseas
respons
death
worldwid
occur
develop
countri
benjamin
et
al
hypertens
main
risk
factor
cardiovascular
diseas
despit
avail
commerci
drug
drug
combin
treat
hypertens
substanti
proport
hypertens
popul
uncontrol
suboptim
control
hypertens
oparil
schmieder
contribut
grow
global
burden
cardiovascular
diseas
oparil
et
al
addit
patient
receiv
treatment
may
suffer
signific
side
effect
angiotensinconvert
enzym
ace
persist
cough
rare
lifethreaten
angioedema
simon
et
al
agah
et
al
ba
stone
brown
suboptim
control
hypertens
associ
target
organ
damag
lead
heart
failur
ischem
heart
diseas
stroke
kidney
dysfunct
retinopathi
vascular
dementia
major
caus
disabl
prematur
death
henc
grow
need
novel
antihypertens
cardiovascular
drug
effect
afford
safe
advers
side
effect
reduc
need
administr
multipl
drug
blood
pressur
cardiovascular
function
regul
multipl
interact
system
includ
larg
part
enzymecatalyz
format
degrad
vasoact
peptid
hormon
overlap
regulatori
system
fig
peptidas
receptor
within
system
import
drug
target
treatment
variou
cardiovascular
diseas
includ
hypertens
heart
failur
coronari
arteri
syndrom
system
reninangiotensin
system
ra
play
central
role
regul
extracellular
fluid
volum
arteri
vasoconstrict
fig
reduct
renal
blood
flow
blood
sodium
level
lead
releas
renin
circul
mostli
renal
juxtaglomerular
cell
wall
affer
arteriol
kidney
davi
freeman
renin
aspartyl
proteas
respons
hydrolyz
serum
globulin
angiotensinogen
releas
peptid
angiotensin
ang
ang
page
helmer
ang
convert
potent
vasoconstrictor
angiotensin
ii
ang
ii
ang
zinc
metalloproteas
ace
highli
express
endotheli
epitheli
cell
vasculatur
kidney
lung
skegg
et
al
shed
circul
unknown
proteas
ehler
et
al
woodman
et
al
ang
ii
main
vasoact
peptid
angiotensin
metabolit
system
ra
elicit
downstream
physiolog
pathophysiolog
effect
predominantli
via
angiotensin
ii
type
receptor
ubiquit
express
cardiovascular
system
bind
result
vasoconstrict
aldosteron
secret
lead
salt
water
retent
ultim
increas
arteri
blood
pressur
ra
regul
neg
feedback
loop
wherebi
ang
ii
reduc
renin
gene
transcript
renal
renin
secret
interact
directli
juxtaglomerular
cell
naftilan
oparil
decreas
flux
pathway
ang
ii
also
mediat
vasodilatori
effect
bind
angiotensin
ii
type
receptor
howev
receptor
express
low
level
cardiovascular
system
healthi
adult
ang
ii
receptor
review
de
gasparo
et
al
drug
target
variou
compon
system
ra
includ
renin
inhibitor
ace
inhibitor
angiotensin
ii
type
receptor
blocker
arb
use
treat
cardiovascular
diseas
atla
mentz
et
al
drug
primarili
design
block
andor
reduc
detriment
effect
ang
ii
howev
increas
evid
addit
ang
ii
mani
angiotensin
peptid
includ
ang
iii
ang
ang
ang
ang
ang
import
physiolog
effect
multipl
amino
endo
carboxypeptidas
involv
produc
rang
angiotensin
metabolit
fig
respons
activ
andor
inhibit
numer
receptor
lead
downstream
physiolog
effect
cardiovascular
protect
peptid
ang
lead
vasodilatori
antiprolif
antiinflammatori
effect
mediat
via
g
receptor
gpcr
ma
santo
et
al
ang
produc
via
peptidasemedi
cleavag
ang
ang
ang
ii
fig
sever
peptidas
form
ang
includ
neprilysin
nep
ace
homolog
vascular
endothelium
prolyl
endopeptidas
smooth
muscl
thimet
oligopeptidas
welch
et
al
chappel
et
al
vicker
et
al
activ
axi
lead
cardiovascular
renalprotect
action
counterregul
harm
action
aceang
pathway
review
santo
et
al
jiang
et
al
patel
et
al
fig
also
accumul
evid
addit
receptor
includ
walter
et
al
ohshima
et
al
shimada
et
al
masrel
gpcr
member
gembardt
et
al
lautner
et
al
tetzner
et
al
function
ang
receptor
receptor
ang
ii
ang
constitut
intric
crossregul
signal
network
review
karnik
et
al
recent
studi
suggest
ang
act
bias
agonist
promot
activ
behav
competit
antagonist
detriment
pathway
initi
ang
ii
galandrin
et
al
addit
yu
et
al
show
metabolit
ang
display
cardioprotect
properti
stimul
releas
cardioprotect
atrial
natriuret
peptid
anp
via
ma
axi
similarli
parent
peptid
ang
ang
current
clinic
trial
treat
diabet
foot
ulcer
cancer
base
abil
stimul
wound
heal
hematopoiet
progenitor
cell
respect
rodger
et
al
savag
et
al
pinter
et
al
exemplifi
divers
function
peptid
ra
also
play
role
convers
ang
ang
albeit
much
lower
effici
convers
ang
ii
ang
addit
counterregulatori
peptid
reduc
advers
cardiovascular
remodel
cardiomyocyt
hypertrophi
cardiac
fibrosi
variou
anim
model
hypertens
myocardi
infarct
subcutan
administr
ocaranza
et
al
et
al
benefici
effect
block
coadministr
antagonist
ma
antagonist
suggest
counterregulatori
effect
independ
axi
mediat
et
al
addit
fattah
et
al
show
gene
therapi
ang
cardioprotect
murin
model
myocardi
infarct
ang
also
competit
inhibitor
ace
therebi
decreas
ang
ii
level
like
ang
shown
potenti
bradykinin
effect
via
receptor
jackman
et
al
angiotensin
metabolit
includ
ang
ang
ang
also
display
uniqu
pharmacolog
effect
biolog
process
beyond
blood
pressur
regul
cardiovascular
function
includ
brain
function
dopamin
regul
insulin
secret
wright
et
al
stragier
et
al
ferreira
et
al
arb
ace
inhibitor
alter
peptid
flux
system
ra
elev
renin
secret
although
ace
inhibitor
particular
lead
promin
increas
plasma
level
ang
potenti
antihypertens
cardioprotect
effect
tabl
ace
primari
enzym
respons
degrad
ang
chappel
et
al
explain
increas
ang
ang
plasma
level
associ
ace
inhibitor
undesir
effect
ace
inhibit
increas
renin
secret
consequ
flux
ra
due
suppress
ang
neg
feedback
loop
process
lead
decreas
pharmacolog
efficaci
ace
inhibitor
longterm
treatment
caus
incomplet
inhibit
ang
ii
format
ang
abundantli
present
substrat
ace
due
high
plasma
renin
activ
result
new
steadi
state
ang
ii
level
longer
suppress
wherea
ang
level
elev
tabl
ace
inhibitor
effect
mani
cardiovascular
diseas
firstlin
treatment
heart
failur
myocardi
infarct
nephropathi
unless
ace
inhibitor
poorli
toler
arb
found
superior
ace
inhibitor
condit
recommend
ace
inhibitor
toler
pitt
et
al
et
al
granger
et
al
yusuf
et
al
recent
activ
agonist
ma
agonist
investig
preclin
model
antihypertens
agent
oppos
harm
effect
ra
tamargo
et
al
kinin
system
key
hormon
pathway
counterregul
overact
ra
kinin
peptid
bestknown
member
bradykinin
bk
potent
vasodil
import
inflammatori
mediat
gener
kininogen
precursor
serin
proteas
kallikrein
fig
regoli
kakoki
smithi
bradykinin
caus
vasodil
induc
prostaglandin
product
increas
vascular
permeabl
fluid
extravas
two
kinin
receptor
identifi
leeblundberg
et
al
vasodilatori
effect
bradykinin
predominantli
mediat
constitut
express
tissu
abund
vascular
endotheli
cell
minim
express
healthi
tissu
induc
tissu
injuri
play
role
chronic
pain
inflamm
bradykinin
cleav
inact
fragment
ace
sever
peptidas
includ
aminopeptidas
p
app
nep
endothelinconvert
enzym
ece
carboxypeptidas
n
dipeptidyl
peptidas
iv
skidgel
et
al
hoang
turner
kuoppala
et
al
fryer
et
al
fig
ace
major
bradykininmetabol
enzym
human
blood
plasma
kuoppala
et
al
accordingli
treatment
ace
inhibitor
result
substanti
increas
bradykinin
level
potenti
vasodilatori
antihypertens
effect
also
crosstalk
ra
kinin
system
benefit
ace
inhibit
partial
attribut
intracellular
inhibitorinduc
acemedi
signal
cascad
lead
chang
gene
express
potenti
bradykinin
respons
inhibit
desensit
benz
et
al
marcic
et
al
tom
et
al
et
al
bradykinin
potenti
howev
doubleedg
sword
although
potent
vasodilatori
effect
ace
inhibitor
attribut
part
increas
level
bradykinin
excess
bradykinin
potenti
seem
associ
principl
side
effect
caus
ace
inhibitor
major
side
effect
persist
cough
also
thought
ace
angioedema
due
increas
bradykinin
israili
hall
fox
et
al
recent
clinic
studi
support
straka
et
al
consid
function
interact
ra
kinin
system
grow
interest
develop
new
drug
target
system
would
greater
efficaci
target
one
system
natriuret
peptid
np
famili
structur
relat
signal
molecul
signal
activ
guanylyl
cyclas
natriuret
vascular
smooth
activ
regul
cardiovascular
skelet
kidney
function
gener
np
cardiovascular
protect
lower
blood
pressur
maintain
fluid
volum
homeostasi
reduc
cardiovascular
fibrosi
review
pandey
three
form
np
anp
btype
natriuret
peptid
bnp
ctype
natriuret
peptid
cnp
process
preprohormon
matur
form
contain
ctermin
disulphid
ring
structur
anp
express
store
primarili
granul
atria
express
lower
level
tissu
includ
ventricl
kidney
anp
releas
primarili
stimul
atrial
wall
stretch
de
bold
et
al
edward
et
al
also
stimul
cardiac
transmur
pressur
well
variou
hormon
stimuli
lachanc
et
al
stasch
et
al
soualmia
et
al
endothelin
ang
ang
although
bnp
origin
isol
brain
commonli
refer
brain
np
predominantli
express
ventricl
heart
transcript
regul
cardiac
wall
stretch
anp
bnp
plasma
level
elev
patient
heart
failur
codi
et
al
rain
et
al
mukoyama
et
al
maisel
et
al
abassi
et
al
contrast
cnp
found
low
level
heart
plasma
level
gener
unchang
heart
failur
wei
et
al
rather
cnp
express
high
concentr
chondrocyt
regul
bone
growth
hagiwara
et
al
addit
cnp
believ
endotheliumderiv
hyperpolar
factor
mediat
relax
vascular
wall
villar
et
al
complex
np
system
increas
presenc
three
type
natriuret
peptid
receptor
npr
classif
specif
role
receptor
extens
review
pandey
briefli
npra
particul
guanylyl
cyclas
pgca
nprb
transmembran
guanyl
cyclas
primarili
respons
physiolog
effect
np
anp
bnp
activ
npra
cnp
activ
nprb
lead
product
secondmesseng
cgmp
nprc
serv
clearanc
receptor
three
peptid
indiscrimin
mediat
np
intern
follow
lysosom
degrad
addit
receptormedi
clearanc
three
np
clear
rapidli
extracellular
matrix
nep
potter
glycosyl
neutral
zinc
endopeptidas
express
high
level
proxim
tubul
cell
kidney
counterregulatori
action
np
detriment
ang
effect
augment
np
system
explor
addit
therapeut
strategi
treatment
hypertens
cardiovascular
diseas
intraven
administr
recombin
form
anp
bnp
improv
clinic
statu
patient
heart
failur
colucci
et
al
suwa
et
al
hata
et
al
connor
et
al
increas
rate
hypotens
short
halfliv
restrict
routin
clinic
use
np
analog
manp
cenderitidenp
heptcyclo
cyshisphedalaglyargdnleaspargileserci
tyr
arg
mimet
nh
resist
enzymat
degrad
act
npr
agonist
current
undergo
clinic
test
approach
investig
extens
increas
circul
np
level
nep
inhibit
normal
condit
nprc
nep
make
similar
contribut
np
clearanc
okolicani
et
al
charl
et
al
howev
patholog
condit
np
level
elev
clearanc
receptor
may
satur
nep
play
signific
role
inhibit
nep
suffici
elev
np
level
hashimoto
et
al
nevertheless
despit
success
develop
potent
nep
inhibitor
effect
increas
np
level
nep
inhibit
prove
use
blood
pressur
control
cardiovascular
function
combin
inhibit
ra
review
campbel
discuss
detail
endothelin
system
fig
function
togeth
ra
maintain
blood
pressur
vascular
tone
precursor
produc
larg
endotheli
cell
process
furan
convertas
peptid
big
itoh
et
al
denault
et
al
big
cleav
anoth
zinc
metallopeptidas
takahashi
et
al
produc
vasoact
peptid
yanagisawa
et
al
kimura
et
al
mediat
potent
vasoconstrictor
action
via
gpcr
endothelin
receptor
b
etar
etbr
respect
jandeleitdahm
mott
et
al
much
like
angiotensin
receptor
exert
oppos
effect
vasoregul
cell
growth
etar
mediat
predomin
respons
associ
patholog
condit
includ
potent
prolong
vasoconstrict
result
irrevers
bind
rubanyi
polokoff
kedzierski
yanagisawa
contrast
endotheli
etbr
mediat
nitric
vasorelax
function
clearanc
receptor
facilit
remov
circul
lysosom
degrad
bremn
et
al
multipl
complex
interact
ra
endothelin
system
includ
posit
dualfeedback
system
ang
ii
increas
express
mrna
function
activ
lead
increas
level
imai
et
al
barton
et
al
rossi
et
al
howev
clinic
condit
preeclampsia
activ
associ
reduc
level
renin
aldosteron
increas
mean
arteri
pressur
verdonk
et
al
natriuret
endothelin
system
also
link
feedback
mechan
wherebi
stimul
releas
np
turn
suppress
action
endothelin
system
stasch
et
al
degrad
nep
vijayaraghavan
et
al
thu
vasodilatori
effect
elev
np
level
caus
nep
inhibitor
may
counterregul
increas
level
endothelin
system
target
therapeut
intervent
due
pathophysiolog
role
hypertens
pulmonari
arteri
hypertens
heart
failur
renal
diseas
diabet
etaretbr
select
etar
antagonist
bosentan
macitentan
ambrisentan
use
clinic
treatment
pulmonari
arteri
hypertens
use
associ
side
effect
includ
edema
anemia
increas
risk
heart
failur
hepat
transamin
wei
et
al
packer
et
al
base
dualfeedback
system
link
endothelin
system
ra
dual
antagonist
develop
test
clinic
pulmonari
arteri
hypertens
essenti
hypertens
chronic
kidney
diseas
murugesan
et
al
neutel
et
al
komer
plotkin
komer
et
al
howev
still
establish
whether
protect
benefit
outweigh
risk
advers
reaction
inhibitor
well
dual
inhibitor
also
develop
show
poor
efficaci
human
dickstein
et
al
biochem
process
involv
gener
vasoact
hormon
peptid
complex
involv
mechan
hormon
format
secret
peptid
cascad
address
articl
two
distinct
mechan
describ
term
stoichiometr
relat
local
correspond
precursor
hormon
wherea
endothelin
np
typic
gener
intracellular
process
membranebound
enzym
local
tissu
russel
davenport
angiotensin
bradykinin
deriv
primarili
liversecret
precursor
peptid
abundantli
present
plasma
serv
virtual
inexhaust
sourc
format
activ
hormon
molecul
throughout
bodi
angiotensinogen
level
human
plasma
rang
women
much
higher
plasma
angiotensinogen
concentr
especi
pregnanc
verdonk
et
al
plasma
concentr
bradykinin
precursor
low
molecular
weight
high
molecular
weight
kininogen
report
low
micromolar
rang
kleniewski
lalmanach
et
al
therefor
plasma
concentr
bradykinin
angiotensin
precursor
higher
plasma
concentr
bk
ang
report
low
picomolar
rang
allow
virtual
unlimit
hormon
synthesi
within
plasma
compart
howev
format
bradykinin
angiotensin
circul
determin
tightli
regul
concentr
activ
enzym
kallikrein
renin
ang
bk
continu
produc
plasma
renin
kallikrein
throughout
bodi
simultan
convert
downstream
metabolit
varieti
solubl
proteas
includ
ace
aminopeptidas
repres
major
metabol
pathway
human
plasma
although
enzymat
composit
plasma
similar
throughout
bodi
local
peptid
hormon
level
differ
due
tissu
express
enzym
receptor
produc
convert
bind
certain
peptid
metabolit
therebi
modifi
baselin
peptid
hormon
profil
establish
intrins
peptid
format
within
plasma
compart
drug
interf
proteas
involv
hormon
metabol
directli
affect
format
degrad
rate
peptid
product
substrat
depend
site
target
express
pharmacodynam
effect
might
seen
plasma
limit
tissu
site
requir
care
select
analyt
approach
aim
establish
relationship
pharmacodynam
physiolog
effect
ace
also
known
peptidyl
dipeptidas
ec
type
membraneanchor
zinc
dipeptidyl
carboxypeptidas
respons
cleavag
divers
set
substrat
includ
angiotensin
peptid
bradykinin
substanc
p
gonadotropinreleas
hormon
lutein
hormonereleas
hormon
ace
exist
two
isoform
somat
ace
test
ace
transcrib
gene
tissuespecif
manner
somat
ace
protein
express
wide
particularli
endotheli
epitheli
cell
test
ace
smaller
form
consist
amino
acid
express
sperm
cell
isoform
consist
heavili
glycosyl
ectodomain
shed
membran
plasma
ace
deriv
endotheli
ace
shed
isoform
kda
concentr
ace
human
plasma
report
rang
ngml
pm
almost
molar
excess
compar
ang
major
substrat
within
ra
fagya
et
al
despit
excess
enzym
substrat
solubl
ace
like
limit
impact
tissu
ang
ii
level
might
depend
local
convers
ang
ang
ii
endotheli
ace
direct
proxim
danser
et
al
ectodomain
somat
ace
consist
two
homolog
catalyt
activ
domain
n
c
domain
wherea
ectodomain
test
ace
consist
c
domain
soubrier
et
al
crystal
structur
individu
n
c
domain
reveal
ellipsoid
shape
mostli
natesh
et
al
corradi
et
al
catalyt
zinc
ion
buri
deep
activesit
caviti
chlorid
ion
typic
observ
two
chlorid
bind
site
activ
site
contain
conserv
hexxh
zinc
bind
motif
contain
two
histidin
residu
coordin
zinc
ion
togeth
conserv
glutam
residu
water
molecul
displac
upon
ligand
coordin
william
et
al
n
c
domain
display
distinct
overlap
substrat
specif
physiolog
function
differ
chlorid
depend
distinct
glycosyl
pattern
wei
et
al
neill
et
al
domain
catalyz
degrad
bradykinin
similar
effici
ndomain
cdomain
knockout
mice
show
similar
bradykinin
plasma
level
wildtyp
mice
van
esch
et
al
bernstein
et
al
suggest
bradykinin
cleavag
one
domain
effect
compens
absenc
domain
contrast
c
domain
primari
site
ang
ii
format
essenti
suffici
control
blood
pressur
vivo
junot
et
al
van
esch
et
al
fuch
et
al
bernstein
et
al
burger
et
al
n
domain
primari
site
clearanc
tetrapeptid
acsdkp
azizi
et
al
junot
et
al
fuch
et
al
potent
antiinflammatori
antifibrot
peptid
consequ
may
desir
select
target
individu
domain
sever
domainspecif
residu
within
activ
site
identifi
import
confer
domain
select
fig
watermey
et
al
et
al
date
structur
individu
domain
complex
varieti
peptid
inhibitor
anoth
import
peptidas
ra
also
known
acerel
carboxypeptidas
ec
type
membraneanchor
zinc
carboxypeptidas
donoghu
et
al
tipni
et
al
cleav
multipl
substrat
includ
vasoact
peptid
involv
patholog
cardiovascular
diseas
convert
ang
ii
ang
remov
ctermin
phenylalanin
residu
tipni
et
al
vicker
et
al
thu
major
compon
counterregulatori
axi
ra
santo
et
al
also
act
ang
produc
ang
albeit
lower
effici
format
ang
particularli
relev
ace
inhibit
ang
abundantli
present
substrat
human
treatment
might
result
profound
increas
ang
basu
et
al
addit
angiotensin
peptid
substrat
within
ra
like
ang
iii
ang
iv
share
c
terminu
prefer
substrat
ang
ii
serv
addit
substrat
still
need
demonstr
vivo
substrat
includ
dynorphin
vicker
et
al
addit
catalyt
function
also
noncatalyt
function
act
function
receptor
coronaviru
caus
sever
acut
respiratori
syndrom
li
et
al
play
role
amino
acid
transport
kowalczuk
et
al
predominantli
local
endotheli
cell
wide
express
within
tissu
includ
heart
kidney
test
brain
intestin
lung
tipni
et
al
protein
singl
catalyt
domain
share
sequenc
ident
n
c
domain
somat
ace
respect
transmembran
region
cytoplasm
tail
distinct
ace
share
close
homolog
collectrin
molecular
chaperon
renal
amino
acid
transport
danilczyk
et
al
inde
act
chaperon
amino
acid
transport
small
intestin
collectrin
express
kowalczuk
et
al
like
ace
glycosyl
ectodomain
shed
membran
releas
circul
shed
disintegrin
metalloproteas
adam
lambert
et
al
although
enzym
respons
ace
shed
yet
identifi
human
circul
detect
healthi
individu
presenc
highli
associ
cardiovascular
risk
factor
studi
involv
healthi
subject
activ
detect
subject
wherea
solubl
level
assay
detect
limit
pm
remain
subject
subject
mean
level
pm
show
stronger
exposur
cardiovascular
risk
factor
includ
abdomin
adipos
hypertens
elev
fast
glucos
lipid
level
rice
et
al
serum
activ
increas
patient
heart
failur
correl
sever
heart
failur
epelman
et
al
report
predict
combin
clinic
endpoint
allcaus
mortal
heart
failur
hospit
heart
transplant
cohort
stabl
patient
chronic
systol
heart
failur
epelman
et
al
catalyt
domain
consist
two
subdomain
link
togeth
hing
region
comparison
inhibitorbound
free
xray
structur
reveal
hingebend
motion
result
chang
rel
posit
subdomain
import
catalysi
towler
et
al
structur
also
reveal
insight
observ
select
rel
ace
show
singl
amino
acid
substitut
hinder
subsit
explain
act
carboxypeptidas
rather
peptidyl
dipeptidas
like
ace
convent
ace
inhibitor
lisinopril
captopril
inhibit
structurebas
method
use
develop
alloster
activ
exploit
conform
differ
observ
crystal
structur
prada
et
al
gjymishka
et
al
activ
bind
surfacebind
pocket
hing
region
lock
protein
activ
conform
activ
shown
antihypertens
cardioprotect
effect
rang
rodent
model
santo
et
al
approach
increas
activ
aim
activ
axi
includ
viral
overexpress
grobe
et
al
oral
intraven
administr
recombin
shenoy
et
al
discuss
detail
section
vii
addit
effect
altern
ra
activ
effici
degrad
ang
ii
turn
reduc
detriment
effect
ang
signal
explain
recombin
shown
efficaci
mani
ang
ii
infus
model
importantli
understand
dynam
ra
respons
administr
activ
vivo
well
crosstalk
pharmacolog
treatment
target
ra
may
major
import
achiev
therapeut
efficaci
complex
patholog
set
vivo
nep
also
known
neutral
endopeptidas
enkephalinas
ec
type
ii
membraneanchor
zincdepend
endopeptidas
origin
purifi
brush
border
rabbit
kidney
kerr
kenni
wide
express
enzym
tether
cell
surfac
larg
ctermin
extracellular
catalyt
domain
respons
cleavag
varieti
physiolog
activ
peptid
includ
np
ang
ang
ii
bradykinin
adrenomedullin
enkephalin
substanc
p
insulin
gastrin
peptid
malfroy
et
al
roqu
et
al
skidgel
turner
tanzawa
iwata
et
al
shirotani
et
al
sever
crystal
structur
solubl
ectodomain
complex
variou
inhibitor
provid
insight
structur
specif
nep
oefner
et
al
sahli
et
al
glossop
et
al
schier
et
al
ectodomain
consist
two
lobe
link
interlac
polypeptid
chain
larg
lobe
structur
similar
zincdepend
bacteri
endopeptidas
thermolysin
contain
catalyt
zinc
bind
motif
hexxh
conserv
motif
residu
involv
zinc
coordin
catalysi
ligand
bind
oefner
et
al
smaller
lobe
absent
relat
bacteri
enzym
act
molecular
siev
limit
size
ligand
da
oefner
et
al
nep
larg
flexibl
activ
site
broader
substrat
specif
ace
prime
side
bind
pocket
primarili
respons
substrat
potenc
select
pocket
display
stringent
specif
preferenti
bind
aromat
larg
hydrophob
group
lloren
et
al
roqu
et
al
larg
subsit
extend
solvent
region
broader
specif
fluiditi
subsit
side
chain
residu
divid
two
pocket
shift
accommod
larg
group
either
site
consequ
howev
simultan
bind
larg
group
subsit
unfavor
would
requir
substanti
induc
fit
requir
backbon
motion
oefner
et
al
ec
name
role
hydrolysi
endothelin
wide
distribut
mammalian
tissu
particularli
high
level
express
cardiovascular
reproduct
endocrin
system
korth
et
al
belong
famili
protein
nep
ectodomain
overlap
specif
high
degre
structur
similar
overal
sequenc
ident
bur
et
al
one
crystal
structur
avail
show
phosphoramidon
bound
within
activ
site
schulz
et
al
reveal
nep
activ
site
share
high
degre
conserv
relationship
sar
studi
seri
phosphin
inhibitor
jullien
et
al
reveal
follow
differ
nep
specif
toler
bulki
group
site
wherea
nep
toler
bulki
group
one
site
toler
stereocent
r
configur
posit
wherea
nep
toler
stereocent
configur
posit
aminopeptidas
apa
ec
homodimer
type
ii
membranebound
monozinc
aminopeptidas
apa
hydrolyz
ntermin
glutam
aspart
residu
peptid
substrat
ang
ii
vitro
nagatsu
et
al
heali
wilk
vivo
brain
migaud
et
al
zini
et
al
activ
enhanc
glenner
et
al
apa
express
variou
tissu
intestin
renal
brush
border
epitheli
cell
vascular
endothelium
within
brain
lojda
gossrau
enzym
also
identifi
sever
brain
nuclei
involv
control
bodi
fluid
homeostasi
cardiovascular
function
zini
et
al
use
crystal
structur
hydrolas
ec
thunnissen
et
al
templat
function
inform
collect
sitedirect
mutagenesi
studi
apa
threedimension
model
mous
apa
ectodomain
residu
includ
activ
site
enzym
built
rozenfeld
et
al
model
zinc
atom
coordin
two
histidin
residu
consensu
sequenc
hexxh
glu
water
molecul
wang
cooper
vazeux
et
al
analysi
apa
model
complex
apa
inhibitor
acid
lejczak
et
al
show
tyr
involv
transit
state
stabil
vazeux
et
al
model
also
demonstr
interact
ntermin
amin
two
glutam
residu
apa
glu
gamen
motif
conserv
among
monozinc
aminopeptidas
glu
respons
apa
exopeptidas
specif
vazeux
et
al
rozenfeld
et
al
introduc
model
apa
local
bottom
subsit
interact
acid
side
chain
asp
asp
ensur
acid
apa
substrat
specif
goto
et
al
claperon
et
al
crystal
structur
human
apa
residu
recent
resolv
yang
et
al
comparison
structur
homolog
mous
apa
model
show
perfect
overlap
apa
activ
site
structur
organ
subsit
subsit
apa
display
stringent
specif
optim
block
acid
aminoacid
residu
glutam
lead
develop
first
specif
select
apa
inhibitor
acid
chauvel
et
al
subsit
hydrophob
wherea
subsit
preferenti
recogn
neg
charg
residu
deriv
aspart
acid
lead
design
apa
inhibitor
subnanomolar
inhibitori
potenc
david
et
al
member
seventransmembran
domain
superfamili
gpcr
nucleic
acid
sequenc
homolog
singl
gene
human
locat
chromosom
encod
protein
rodent
howev
two
subtyp
b
locat
chromosom
respect
highli
conserv
code
region
sandberg
et
al
wide
express
well
conserv
speci
de
gasparo
et
al
ang
ii
activ
number
signal
pathway
g
gq
gi
janu
kinasesign
transduc
activ
transcript
mitogenactiv
protein
kinas
extracellular
signalregul
kinas
pathway
caus
hypertens
endotheli
dysfunct
vascular
remodel
end
organ
damag
addit
g
signal
adapt
protein
distinct
function
physiolog
consequ
rajagop
et
al
conform
stabil
peptid
agonist
differ
ang
conform
agonist
signific
impact
pharmacolog
alter
intracellular
traffick
receptor
addit
activ
signal
pathway
namkung
et
al
form
homo
heterodim
gpcr
mani
dimer
link
alter
abil
activ
g
protein
andor
abdalla
et
al
hansen
et
al
et
al
ang
ii
ang
iii
similar
bind
affin
thu
express
receptor
regul
receptor
subtyp
mediat
respons
ang
ii
ang
iii
rabey
et
al
bosnyak
et
al
moreov
crosstalk
result
stimul
one
receptor
modul
express
abdalla
et
al
highresolut
crystal
structur
human
complex
select
antagonist
methyl
one
precursor
antihypertens
candesartan
provid
fundament
insight
relationship
receptor
zhang
et
al
surprisingli
three
residu
arg
tyr
trp
previous
shown
make
interact
ligand
made
import
contact
antagonist
addit
mutagenesi
dock
studi
reveal
residu
critic
peptid
nonpeptid
bind
exploit
interact
pave
way
new
mechanist
studi
therapeut
strategi
gene
locat
human
chromosom
x
encod
gpcr
molecular
mass
kda
kambayashi
et
al
contrast
activ
phosphatas
mitogenactiv
protein
kinas
phosphatas
protein
phosphatas
import
signal
mechan
kang
et
al
yamada
et
al
furthermor
coupl
gi
protein
stimul
ion
channel
current
kang
et
al
crystal
structur
complex
ligand
show
helix
noncanon
posit
stabil
activ
state
gpcr
moreov
interact
prevent
bind
g
protein
provid
molecular
basi
altern
gprotein
signal
zhang
et
al
although
signal
mechan
fulli
understood
similar
ma
signal
involv
protein
tyrosin
phosphotas
phosphoinositid
nitric
oxid
synthas
seguin
et
al
addit
ma
form
heterodim
ang
effect
block
antagonist
physiolog
level
express
low
howev
express
level
found
higher
develop
disappear
adult
rat
except
brain
ovari
uteru
cook
et
al
millan
et
al
pucel
et
al
song
et
al
lenkei
et
al
liver
kidney
rat
compar
neonat
yu
et
al
gene
express
regul
numer
factor
includ
intracellular
calcium
protein
kinas
c
kijima
et
al
insulin
kambayashi
et
al
multipl
growth
factor
ichiki
et
al
mediat
varieti
protect
action
immun
modul
antifibrot
antiinflammatori
neuroprotect
neuroregener
antihypertens
antiapoptot
action
namsolleck
et
al
steckel
et
al
thu
number
agonist
develop
therapeut
intervent
provid
import
inform
futur
prospect
drug
target
santo
et
al
ma
also
call
protooncogen
first
identifi
member
masrel
gpcr
subfamili
protein
consist
seven
transmembran
domain
typic
gpcr
review
bader
et
al
first
describ
oncogen
base
human
oncogen
assay
human
ma
gene
purifi
tumor
induc
nude
mous
inject
anim
nih
cell
cotransfect
dna
purifi
human
tumor
young
et
al
howev
studi
show
ma
transform
cell
artifici
overexpress
rabin
et
al
van
veer
et
al
suggest
oncogen
initi
report
ma
origin
propos
function
receptor
ang
ii
jackson
et
al
also
later
disprov
subsequ
signal
experi
ambroz
et
al
clone
murphi
et
al
sasaki
et
al
discoveri
ma
interact
directli
explain
indirect
involv
ma
ang
ii
signal
kosteni
et
al
ma
identifi
function
receptor
ang
respons
benefici
physiolog
effect
ang
santo
et
al
make
key
compon
counterregulatori
axi
ra
potenti
target
therapeut
intervent
subsequ
studi
provid
addit
evid
support
show
specif
label
tissuescel
line
label
ang
lost
masdefici
animalscel
tallant
et
al
fragasilva
et
al
leal
et
al
howev
recent
extens
biochem
studi
unabl
support
direct
interact
ang
ma
gaidarov
et
al
bring
question
whether
ang
inde
endogen
agonist
receptor
addit
ang
sever
put
ma
agonist
includ
ave
methyl
phenyl
sulfonylurea
wiemer
et
al
amino
acid
sequenc
flgysiylnrkrrgdpafkrrlrd
pinheiro
et
al
savergnini
et
al
antagonist
ang
santo
et
al
ang
santo
et
al
use
studi
action
ma
although
rigor
analysi
ma
bind
affin
lack
ma
agonist
shown
rang
cardioprotect
effect
anim
model
review
bader
et
al
endogen
peptid
abl
act
ma
agonist
also
report
jankowski
et
al
tirupula
et
al
yu
et
al
like
mani
gpcr
ma
display
bias
agon
differ
ligand
activ
differ
downstream
pathway
bader
et
al
karnik
et
al
potenti
downstream
signal
pathway
ma
stimul
ang
relat
analog
includ
phospholipas
pathway
gener
arachidon
acid
santo
et
al
phosphoinositid
pathway
lead
activ
endotheli
nitric
oxid
synthas
sampaio
et
al
lopez
verrilli
et
al
savergnini
et
al
et
al
ang
activ
ma
glomerular
mesangi
cell
camp
depend
thought
mediat
protect
action
experiment
model
renal
injuri
liu
et
al
masmedi
activ
phospholipas
signal
pathway
report
agonist
includ
endogen
ligand
neuropeptid
ff
ang
shemesh
et
al
zhang
et
al
tirupula
et
al
ma
express
highest
level
brain
testi
found
low
level
wide
rang
organ
function
ma
gpcr
variou
tissu
review
bader
et
al
current
highresolut
structur
masrel
gpcr
dual
acenep
inhibitor
first
vasopeptidas
inhibitor
enter
clinic
trial
develop
simultan
block
acemedi
format
vasoconstrictor
ang
ii
nepmedi
degrad
np
vasodil
eleven
dual
acenep
inhibitor
test
vari
extent
clinic
dimitropoulo
et
al
omapatrilat
progress
furthest
eventu
fail
obtain
us
food
drug
administr
fda
approv
larg
phase
iii
clinic
trial
due
report
increas
risk
angioedema
earli
dual
inhibitor
design
ration
base
specif
ace
nep
inhibitor
combin
benzyl
group
known
import
nep
inhibit
prolin
group
seen
first
ace
inhibitor
eg
captopril
led
seri
potent
mercaptoacyl
dipeptid
dual
inhibitori
activ
robl
et
al
turcaud
et
al
sar
studi
optim
vivo
activ
led
conform
restrict
dipeptid
mimet
eventu
omapatrilat
bicycl
thiazepinon
robl
et
al
omapatrilat
display
potent
inhibit
low
nanomolar
rang
ace
nep
vitro
well
chronic
potent
antihypertens
cardioprotect
effect
experiment
model
hypertens
heart
failur
robl
et
al
trippodo
et
al
intengan
schiffrin
pu
et
al
earli
preliminari
clinic
data
also
promis
test
dose
omapatrilat
show
potent
antihypertens
effect
drug
class
test
appear
effect
improv
cardiac
function
patient
heart
failur
howev
concern
omapatrilatassoci
angioedema
studi
efficaci
safeti
omapatrilat
larg
random
clinic
trial
undertaken
assess
efficaci
safeti
profil
omapatrilat
patient
hypertens
heart
failur
compar
convent
ace
inhibitor
enalapril
coat
octav
omapatrilat
cardiovascular
treatment
assess
versu
enalapril
trial
includ
hypertens
patient
show
antihypertens
efficaci
omapatrilat
disappointingli
rate
angioedema
higher
observ
enalapril
vs
case
angioedema
tend
occur
earlier
sever
omapatrilat
group
kosti
et
al
overtur
omapatrilat
versu
enalapril
random
trial
util
reduc
event
carri
patient
show
omapatrilat
good
better
enalapril
reduc
primari
endpoint
event
patient
heart
failur
packer
et
al
although
incid
angioedema
lower
overtur
octav
rate
angioedema
still
higher
omapatrilat
group
vs
base
overtur
octav
trial
fda
conclud
benefit
treat
patient
hypertens
heart
failur
omapatrilat
outweigh
risk
zanchi
et
al
sinc
ace
nep
contribut
breakdown
bradykinin
bradykinin
accumul
associ
angioedema
fox
et
al
molinaro
et
al
thought
increas
risk
seriou
potenti
lifethreaten
complic
would
also
affect
dual
acenep
inhibitor
halt
develop
oncepromis
class
drug
although
conceiv
chang
rel
level
ace
nep
inhibit
could
improv
efficaci
safeti
profil
dual
inhibitor
promis
earlystag
clinic
trial
inhibitor
report
year
omapatrilat
studi
azizi
et
al
johnson
et
al
largescal
trial
inhibitor
conduct
also
worth
note
omapatrilat
offtarget
effect
may
contribut
poor
side
effect
profil
could
differ
offtarget
effect
inhibitor
class
omapatrilat
failur
clinic
discov
omapatrilat
inhibit
third
zinc
metallopeptidas
involv
bradykinin
inactiv
app
ki
sulpizio
et
al
fryer
et
al
fryer
et
al
show
bradykinin
degrad
rat
enzym
rank
efficaci
ace
app
nep
suggest
app
inhibit
may
contribut
significantli
increas
kininmedi
side
effect
observ
omapatrilat
recent
enzym
structur
data
confirm
omapatrilat
nonselect
potent
inhibitor
ace
domain
interact
conserv
residu
within
n
c
domain
activ
site
cozier
et
al
dual
acenep
inhibitor
also
result
elev
peptid
like
bradykinin
increas
endotheli
nitric
oxid
level
may
also
contribut
angioedema
advers
effect
includ
flush
dual
inhibitor
also
explor
increas
efficaci
nep
inhibit
inhibit
prevent
format
therebi
avoid
accumul
observ
inhibit
nep
primari
enzym
respons
degrad
fig
discoveri
phosphoramidon
inhibit
addit
nep
initi
develop
dual
inhibitor
xu
et
al
kukkola
et
al
howev
advanc
dual
inhibitor
daglutril
slv
despit
effect
elev
plasma
np
big
level
dosedepend
manner
ineffect
lower
system
blood
pressur
clinic
studi
dickstein
et
al
suggest
effect
antihypertens
treatment
must
incorpor
blockad
ra
anoth
strategi
simultan
block
ra
np
degrad
format
tripl
inhibitor
inhibitor
expect
show
improv
efficaci
dual
inhibitor
reduc
need
polypharmaci
safeti
issu
concern
extens
studi
tripl
vasopeptidas
inhibitor
ltryptophan
n
amino
cyclopentyl
carbonyl
central
cyclic
nonnatur
amino
acid
tryptophan
accommod
site
three
enzym
show
good
efficaci
variou
rat
model
hypertens
addit
although
treatment
result
signific
accumul
bradykinin
nitric
oxid
level
substanti
reduc
compar
treatment
omapatrilat
daull
et
al
yet
shown
whether
decreas
plasma
concentr
associ
reduct
nitric
oxid
releas
compens
elev
bradykinin
level
even
though
preclin
test
rat
show
toxic
effect
daull
et
al
tripl
vasopeptidas
inhibitor
yet
test
human
effect
broadspectrum
inhibitor
vasopeptid
level
need
care
evalu
due
complex
interconnect
pathway
offtarget
effect
also
need
minim
ensur
activ
addit
enzym
involv
kinin
inactiv
app
carboxypeptidas
n
affect
advers
reaction
associ
ace
inhibitor
vasopeptidas
inhibitor
like
due
undesir
effect
peptid
level
besid
ang
ii
particularli
bradykinin
peptid
substanc
p
forth
may
also
contribut
advers
effect
occur
patient
steckel
et
al
weber
messerli
astound
consid
ace
inhibitor
routin
use
treat
larg
number
patient
decad
although
current
evid
suggest
vasopeptidas
inhibitor
potenti
effect
convent
ace
inhibitor
safeti
profil
remain
concern
ace
inhibitor
vasopeptidas
inhibitor
target
n
c
domain
ace
test
clinic
prior
knowledg
differ
role
ace
domain
well
establish
c
domain
predominantli
respons
ang
ii
format
vivo
domain
inactiv
bradykinin
similar
rate
select
inhibit
c
domain
potenti
reduc
accumul
bradykinin
level
peptid
cleav
n
domain
ace
inhibitor
treatment
multipl
crystal
structur
inhibitor
complex
individu
ace
n
c
domain
nep
provid
molecular
insight
enzym
specif
function
togeth
increas
knowledg
integr
network
ra
np
kallikreinkinin
system
endothelin
system
sever
decad
sar
studi
enzym
provid
strong
foundat
design
nextgener
inhibitor
knowledg
ace
sequenc
structur
individu
domain
facilit
develop
n
ace
inhibitor
inhibitor
may
prove
use
indic
fibrosi
would
benefici
inhibit
acsdkp
format
without
affect
blood
pressur
dive
et
al
dougla
et
al
fienberg
et
al
vitro
mutagenesi
studi
residu
systemat
mutat
ndomain
counterpart
vice
versa
provid
valuabl
inform
interact
import
confer
domain
select
watermey
et
al
et
al
watermey
et
al
fig
sever
inhibitor
typic
deriv
nonselect
ace
inhibitor
develop
show
greater
two
order
magnitud
select
c
domain
vitro
compound
includ
ketomethylen
inhibitor
kaw
kaf
nchinda
et
al
watermey
et
al
deriv
moder
cselect
compound
kap
almquist
et
al
deddish
et
al
phosphin
inhibitor
georgiadi
et
al
et
al
carboxyl
inhibitor
lisw
nchinda
et
al
watermey
et
al
deriv
convent
inhibitor
lisinopril
fig
crystal
structur
inhibitor
complex
c
domain
reveal
bulki
hydrophob
residu
bind
pocket
common
featur
inhibitor
typic
confer
observ
cdomain
select
corradi
et
al
watermey
et
al
mutat
data
suggest
cooper
effect
number
residu
within
subsit
contribut
select
compound
addit
residu
subsit
also
play
role
sever
bradykininpotenti
peptid
first
compound
identifi
antihypertens
properti
also
display
cdomain
select
cotton
et
al
structur
select
bradykininpotenti
peptid
bppb
complex
c
domain
masuy
et
al
n
domain
togeth
mutagenesi
studi
provid
structur
basi
select
peptid
sturrock
et
al
provid
addit
insight
design
select
inhibitor
ex
vivo
vivo
studi
lisw
extens
studi
inhibitor
confirm
inhibit
pharmacolog
relev
result
uniqu
vasopeptid
metabol
profil
compar
nonselect
ace
inhibitor
studi
hypertens
mice
express
activ
human
renin
show
lisw
reduc
blood
pressur
ang
ii
level
similarli
lisinopril
without
increas
bradykinin
level
burger
et
al
anoth
studi
rat
myocardi
infarct
determin
pharmacodynam
effect
lisw
angiotensin
metabolit
acsdkp
level
sharp
et
al
lisinopril
lisw
decreas
ang
ratio
acsdkp
level
confirm
lisw
inhibit
c
domain
select
sinc
ang
acsdkp
substrat
deddish
et
al
base
vivo
data
lisw
ace
inhibitor
offer
hope
new
gener
ace
inhibitor
improv
safeti
unlik
offer
improv
efficaci
unless
combin
drug
class
inhibitor
yet
test
clinic
jullien
et
al
taken
concept
one
step
develop
dual
ace
inhibitor
inhibitor
design
inhibit
format
vasoconstrictor
ang
ii
leav
ace
n
domain
nep
free
degrad
bradykinin
jullien
et
al
structurebas
design
initi
base
structur
inhibitor
dual
inhibitor
phosphoramidon
led
seri
phosphin
tripeptid
stereochemistri
bulki
bicycl
residu
prove
import
discrimin
nep
illustr
differ
inhibit
constant
observ
compound
fi
fii
fig
unusu
r
configur
residu
fii
highli
select
nep
maintain
potent
ace
cdomain
activ
crystal
structur
ace
c
domain
n
domain
complex
compound
unexpectedli
reveal
bulki
group
accommod
pocket
four
structur
highlight
fluiditi
pocket
pocket
abil
accommod
conform
divers
bulki
hydrophob
group
fig
akif
et
al
masuy
et
al
anoth
surpris
find
addit
fii
inhibitor
molecul
occupi
cdomain
activ
site
bind
nonprim
side
first
molecul
fii
promis
dual
ace
inhibitor
display
cdomain
select
select
nep
administr
fii
hypertens
rat
result
antihypertens
effect
jullien
et
al
effect
fii
bradykinin
level
metabol
vasoact
peptid
report
compound
display
high
select
c
domain
n
domain
still
inhibit
n
domain
nanomolar
rang
differ
ki
n
domain
confirm
inhibitor
result
distinct
peptid
metabol
profil
compar
convent
dual
inhibitor
vivo
also
still
report
may
unnecessari
leav
ace
n
domain
nep
free
degrad
bradykinin
sinc
ace
primari
bradykininmetabol
enzym
fryer
et
al
n
domain
may
compens
suffici
c
domain
prevent
buildup
danger
level
bradykinin
consequ
dual
ace
inhibitor
could
offer
promis
altern
treatment
hypertens
cardiovascular
diseas
potenti
np
level
addit
block
ang
ii
format
parallel
dual
ace
inhibitor
dualact
angiotensinreceptornep
inhibitor
sacubitrilvalsartan
call
entresto
novarti
east
hanov
nj
novel
drug
formul
contain
equimolar
amount
arb
valsartan
nep
inhibitor
sacubitril
prodrug
sacubitrilvalsartan
first
new
class
drug
combin
nep
inhibit
togeth
ang
ii
receptor
blockad
gu
et
al
ruilop
et
al
mcmurray
et
al
vardeni
et
al
similar
dual
ace
inhibitor
drug
combin
serv
enhanc
nep
activ
inhibit
detriment
effect
ra
effect
bradykinin
nepderiv
vasoprotect
factor
sacubitrilvalsartan
evalu
manag
hypertens
heart
failur
reduc
eject
fraction
hfref
heart
failur
preserv
eject
fraction
hfpef
demonstr
clinic
efficaci
reduct
blood
pressur
patient
essenti
hypertens
without
hfpef
reduct
hospit
mortal
patient
hfref
landmark
clinic
trial
paradigmhf
prospect
comparison
arni
acei
determin
impact
global
mortal
morbid
heart
failur
show
sacubitrilvalsartan
significantli
effect
treatment
heart
failur
hfref
compar
enalapril
mcmurray
et
al
mogensen
et
al
sacubitrilvalsartan
approv
fda
treatment
hfref
drug
includ
american
yanci
et
al
european
ponikowski
et
al
clinic
guidelin
treatment
heart
failur
despit
robust
evid
clinic
benefit
seen
paradigmhf
trial
well
inclus
drug
clinic
guidelin
medic
approv
unit
state
treatment
heart
failur
prescrib
new
therapeut
slow
ascrib
phenomenon
clinic
inertia
jarcho
driven
clinician
unfamiliar
reluct
switch
stabl
patient
safeti
concern
payerreimburs
issu
sauer
et
al
recent
studi
estim
death
could
prevent
year
unit
state
optim
implement
sacubitrilvalsartan
therapi
fonarow
et
al
thu
potenti
reduct
mortal
could
substanti
call
paradigm
shift
warrant
clinic
practic
sauer
et
al
pioneerhf
studi
comparison
sacubitrilvalsartan
versu
enalapril
effect
ntprobnp
patient
stabil
acut
heart
failur
episod
show
treatment
sacubitrilvalsartan
produc
significantli
greater
reduct
ntermin
natriuret
peptid
ntprobnp
level
enalapril
without
increas
rate
major
advers
event
patient
hospit
acut
decompens
heart
failur
velazquez
et
al
may
help
overcom
clinic
inertia
jarcho
angiotensin
inhibitor
arni
shown
consider
cardiovascular
benefit
absolut
risk
reduct
compar
standardofcar
treatment
paradigm
yandrap
et
al
pioneerhf
morrow
et
al
velazquez
et
al
trial
composit
endpoint
explor
part
prespecifi
exploratori
analysi
consist
death
rehospit
heart
failur
hospit
stay
hour
requir
left
ventricular
assist
devic
insert
list
cardiac
transplant
furthermor
recent
metaanalysi
data
paradigmhf
trial
srivastava
et
al
show
estim
number
need
treat
primari
outcom
cardiovascular
death
heart
failur
hospit
arni
therapi
increment
ace
inhibitor
therapi
overal
cohort
valu
consid
clinic
meaning
support
guidelin
recommend
use
arni
therapi
among
elig
patient
hfref
therapeut
role
arni
hfpef
still
unclear
current
investig
howev
effect
longterm
nep
inhibit
yet
establish
nep
respons
metabol
mani
peptid
thu
chronic
inhibit
may
rang
physiolog
effect
inde
much
nep
inhibit
angiotensin
receptor
blockad
may
increas
chronic
therebi
diminish
blood
potenti
combin
like
upregul
sodiumhydrogen
exchang
kidney
constrictor
etbr
vascular
wall
roksnoer
et
al
chronic
nep
inhibit
may
addit
influenc
alzheim
diseas
progress
due
nep
role
degrad
peptid
date
concentr
shown
increas
cerebrospin
fluid
healthi
volunt
treat
sacubitrilvalsartan
langenickel
et
al
increas
cognit
defect
versu
enalapril
paradigmhf
trial
cannon
et
al
perspect
trial
evalu
efficaci
safeti
compar
valsartan
cognit
function
patient
chronic
heart
failur
preserv
eject
fraction
collect
data
longterm
cognit
effect
patient
chronic
heart
failur
treat
sacubitrilvalsartan
valsartan
sauer
et
al
furthermor
sacubitrilvalsartan
may
effect
inflamm
polyneuropathi
bronchial
reactiv
cancer
recent
review
detail
campbel
longterm
clinic
data
treatment
sacubitrilvalsartan
provid
inform
benefici
advers
effect
chronic
inhibit
import
develop
new
vasopeptidas
inhibitor
potenti
futur
indic
sacubitrilvalsartan
includ
myocardi
infarct
hfpef
diabet
nephropathi
stroke
arni
attenu
advers
cardiac
remodel
dysfunct
myocardi
infarct
rat
compar
ace
inhibitor
perindopril
kompa
et
al
preserv
left
ventricular
eject
fraction
myocardi
infarct
rabbit
wherea
valsartan
torrado
et
al
studi
patient
hfpef
show
week
treatment
arni
lower
ntprobnp
strongli
valsartan
solomon
et
al
hfpef
account
larg
percentag
patient
heart
failur
associ
signific
morbid
mortal
current
medic
suboptim
new
therapi
sought
includ
sacubitrilvalsartan
paragonhf
prospect
comparison
arni
arb
global
outcom
hf
preserv
eject
fraction
trial
design
determin
efficaci
safeti
sacubitrilvalsartan
combin
compar
valsartan
solomon
et
al
paragonhf
eventdriven
trial
random
patient
follow
least
total
heart
failur
hospit
cardiovascular
death
occur
studi
ongo
provid
import
inform
potenti
therapeut
use
sacubitrilvalsartan
hfpef
arni
may
also
effect
cardiovascular
diseas
associ
diabet
rat
made
diabet
streptozotocin
nep
inhibitor
thiorphan
combin
arb
prevent
function
renal
declin
improv
glomerulosclerosi
fibrosi
inflamm
versu
arb
alon
roksnoer
et
al
malek
et
al
secondari
analysi
patient
heart
failur
type
diabet
paradigmhf
trial
also
reveal
arni
attenu
effect
diabet
acceler
renal
deterior
damman
et
al
packer
et
al
yet
arni
display
similar
effect
kidney
function
albuminuria
irbesartan
patient
chronic
kidney
diseas
although
display
superior
blood
pressur
effect
hayn
et
al
remark
complet
prevent
stroke
obtain
arni
valsartan
strokepron
spontan
hypertens
rat
shr
rubattu
et
al
although
bai
et
al
observ
arni
prevent
ischem
brain
damag
middl
cerebr
arteri
occlus
much
mark
manner
valsartan
given
promis
effect
full
understand
mechan
action
arni
urgent
need
studi
often
report
increas
bnp
decreas
ntprobnp
latter
inact
sideproduct
yield
upon
cleavag
probnp
biolog
activ
bnp
elev
serum
ntprobnp
well
known
marker
heart
failur
sever
associ
increas
risk
mortal
hospit
ntprobnp
degrad
nep
thu
longer
halflif
bnp
decreas
ntprobnp
level
suggest
reduc
probnp
product
due
reduc
cardiac
wall
tension
eg
due
blood
pressur
lower
wherea
increas
bnp
either
suggest
opposit
might
due
nep
inhibit
henc
combin
blood
pressur
lower
nep
inhibit
may
even
result
chang
bnp
level
furthermor
decreas
ntprobnp
rise
bnp
report
might
also
assay
artifact
due
fact
arni
promot
peptid
glycosyl
therebi
affect
assay
ntprobnp
bnp
ntprobnp
would
becom
invis
probnp
would
addit
detect
bnp
assay
et
al
anoth
complic
factor
bnp
np
least
suscept
degrad
nep
thu
act
endogen
inhibitor
nep
patient
elev
bnp
level
alreadi
undergo
nep
inhibit
accordingli
may
less
respons
arni
vodovar
et
al
enzymat
convers
proinflammatori
profibrot
vasoconstrictor
ang
ii
antiinflammatori
antifibrot
cardioprotect
vasodil
ang
appear
reason
therapeut
approach
treat
condit
ang
ii
shown
involv
patholog
mechan
ang
could
mediat
protect
effect
therefor
recombin
human
angiotensinconvert
enzym
current
consid
treat
acut
respiratori
distress
syndrom
pulmonari
arteri
hypertens
safeti
toler
studi
healthi
volunt
singl
dose
administ
intraven
reveal
plasma
halflif
enzym
rang
hour
peak
plasma
concentr
nm
highestdos
cohort
plasma
level
stay
rang
nm
hour
administr
singl
dose
haschk
et
al
compar
undetect
level
present
healthi
volunt
pm
rice
et
al
increas
circul
level
achiev
least
hour
administr
moder
intraven
dose
recombin
enzym
although
signific
decreas
blood
pressur
could
detect
healthi
volunt
treatment
show
expect
biochem
vivo
profound
suppress
circul
ang
ii
ang
ang
level
increas
haschk
et
al
recent
pilot
trial
conduct
patient
acut
respiratori
distress
syndrom
clinicaltrialsgov
identifi
convers
ang
ii
ang
ang
could
confirm
compound
well
toler
although
trend
reduc
level
report
subject
signific
chang
observ
ratio
partial
pressur
arteri
oxygen
fraction
inspir
oxygen
oxygen
index
sequenti
organ
failur
assess
score
studi
termin
includ
patient
interim
analysi
reveal
unlikeli
reach
signific
outcom
primari
outcom
includ
safeti
toler
success
reach
rapid
modul
angiotensin
metabolit
level
also
observ
individu
patient
circul
ang
ii
level
pm
indic
pharmacolog
efficaci
achiev
state
high
ra
activ
one
reason
lack
effect
might
larg
heterogen
baselin
ra
activ
popul
although
reflect
realiti
khan
et
al
given
ang
format
critic
depend
avail
ang
ii
primari
substrat
patient
stratif
basi
renin
ang
ii
might
reason
approach
enhanc
therapeut
efficaci
observ
treatment
aim
reduc
ang
ii
level
promot
altern
ra
via
increas
ang
format
two
studi
investig
intraven
administr
current
recruit
patient
first
conduct
human
healthi
volunt
acut
hypoxia
exercis
placebocontrol
crossov
design
modif
pulmonari
arteri
systol
pressur
serv
primari
outcom
second
studi
openlabel
dose
escal
studi
patient
pulmonari
arteri
hypertens
chang
pulmonari
vascular
resist
cardiac
output
mean
pulmonari
arteri
pressur
respons
serv
primari
outcom
measur
endogen
predominantli
express
endotheli
surfac
varieti
tissu
includ
heart
kidney
lung
tipni
et
al
angiotensin
metabolit
continu
gener
blood
plasma
process
mainli
driven
kidneyderiv
renin
hepat
angiotensinogen
membranebound
ace
aminopeptidas
inde
endotheli
surfac
play
key
role
gener
local
ra
modifi
angiotensin
mix
suppli
blood
natur
environ
like
compet
local
ang
ii
extent
balanc
system
affect
excess
circul
differ
state
ra
activ
eg
high
amount
affect
plasma
angiotensin
substrat
suppli
endotheli
surfac
absenc
presenc
compensatori
mechan
obvious
critic
clinic
success
requir
investig
sever
decad
investig
provid
evid
exist
brain
ra
involv
control
cardiovascular
function
veerasingham
raizada
sakai
sigmund
compon
system
precursor
angiotensinogen
enzym
renin
ace
apa
aminopeptidas
n
apn
peptid
ang
ang
ii
ang
iii
ang
receptor
well
present
within
brain
review
lenkei
et
al
wright
hard
santo
et
al
whether
local
origin
deriv
plasma
remain
matter
debat
sigmund
et
al
van
thiel
et
al
brain
ra
hyperact
implic
develop
mainten
hypertens
sever
experiment
genet
anim
model
hypertens
shr
deoxycorticosteron
acet
doca
salt
rat
transgen
mice
overexpress
angiotensinogen
renin
human
gene
basso
et
al
ganten
et
al
davisson
et
al
among
bioactiv
peptid
ra
ang
ii
ang
iii
display
similar
affin
wright
hard
inject
brain
peptid
similarli
increas
blood
pressur
argininevasopressin
releas
phillip
zini
et
al
reaux
et
al
howev
ang
ii
convert
ang
iii
vivo
natur
effector
peptid
brain
ra
remain
defin
use
radiolabel
angiotensin
presenc
absenc
specif
select
apa
apn
inhibitor
chauvel
et
al
butan
thiol
et
al
respect
administ
intracerebroventricular
rout
brain
apa
shown
gener
ang
iii
ang
ii
remov
ntermin
aspart
residu
wherea
apn
ec
anoth
membranebound
zinc
metalloproteas
metabol
ang
iii
ang
iv
zini
et
al
use
inject
alon
central
rout
show
endogen
ang
iii
rather
ang
ii
one
main
effector
peptid
brain
ra
control
blood
pressur
argininevasopressin
releas
zini
et
al
reaux
et
al
wright
et
al
fourniezaluski
et
al
brain
ang
iii
exert
tonic
stimulatori
control
blood
pressur
two
experiment
model
hypertens
shr
reaux
et
al
marc
et
al
docasalt
rat
fourniezaluski
et
al
model
exhibit
hyperact
brain
ra
activ
system
ra
normal
shr
model
depress
docasalt
rat
character
low
plasma
renin
level
high
plasma
argininevasopressin
level
account
resist
hypertens
docasalt
rat
treatment
system
ra
blocker
brain
apa
enzym
respons
gener
brain
ang
iii
therefor
constitut
promis
target
hypertens
treatment
justifi
develop
potent
select
apa
inhibitor
centralact
antihypertens
agent
prodrug
bi
sulfon
acid
renam
firibastat
develop
clinic
use
fourniezaluski
et
al
compound
compos
two
molecul
link
disulfid
bridg
oral
administ
cross
intestin
hepat
barrier
upon
brain
entri
disulfid
bridg
rapidli
cleav
brain
reductas
gener
two
activ
molecul
inhibit
brain
apa
activ
block
format
brain
ang
iii
fourniezaluski
et
al
decreas
blood
pressur
argininevasopressin
releas
alert
hypertens
rat
bodineau
et
al
marc
et
al
blood
pressur
decreas
due
follow
decreas
sympathet
tone
consequ
vascular
resist
decreas
argininevasopressin
releas
bloodstream
posterior
pituitari
reduc
extracellular
volum
improv
baroreflex
function
fig
bodineau
et
al
marc
et
al
huang
et
al
blood
pressur
effect
note
normotens
rat
show
antihypertens
agent
hypotens
agent
moreov
blood
pressur
decreas
greater
hypertens
docasalt
rat
shr
suggest
may
especi
effect
saltdepend
hypertens
togeth
data
led
first
evalu
human
clinic
studi
healthi
volunt
singl
ascend
oral
dose
phase
ia
multipl
oral
dose
phase
ib
shown
well
toler
balavoin
et
al
mg
twice
daili
day
two
phase
ii
clinic
trial
conduct
first
phase
iia
trial
carri
hypertens
patient
grade
ii
random
doubleblind
studi
compar
effect
mg
twice
daili
week
mg
twice
daili
week
placebo
azizi
et
al
intentiontotreat
popul
daytim
ambulatori
systol
blood
pressur
sbp
offic
sbp
decreas
mm
hg
respect
week
firibastat
treatment
versu
placebo
differ
group
statist
signific
p
p
respect
perprotocol
popul
n
patient
firibastat
treatment
induc
larger
decreas
daytim
ambulatori
sbp
median
mm
hg
interquartil
rang
patient
basal
valu
daytim
ambulatori
sbp
mm
hg
wherea
placebo
treatment
induc
chang
median
mm
hg
interquartil
rang
multipl
linear
regress
analysi
perprotocol
popul
treatment
firibastat
p
baselin
daytim
ambulatori
sbp
p
associ
chang
daytim
ambulatori
sbp
suggest
basal
daytim
ambulatori
sbp
elev
firibastatinduc
sbp
decreas
appar
agreement
observ
experiment
model
hypertens
firibastat
act
antihypertens
agent
hypotens
agent
studi
show
treatment
safe
tend
decreas
daytim
ambulatori
sbp
significantli
azizi
et
al
possibl
due
small
number
patient
short
durat
treatment
data
use
guid
design
larg
phase
iib
clinic
trial
newhop
novel
evalu
hypertens
overweight
patient
multipl
ethnic
origin
carri
overweight
hypertens
patient
sbp
mm
hg
selfidentifi
african
american
hispan
patient
receiv
firibastat
month
mg
twice
daili
oral
week
mg
twice
daili
mg
hydrochlorothiazid
daili
could
ad
month
sbp
mm
hg
andor
dbp
mm
hg
signific
blood
efficaci
safe
toler
profil
observ
ferdinand
et
al
proof
concept
firibastat
efficaci
confirm
pivot
phase
iii
trial
could
constitut
first
new
class
central
act
antihypertens
agent
firibastat
may
especi
effect
african
american
poorli
respons
blocker
system
ra
salt
sensit
high
plasma
argininevasopressin
level
low
plasma
renin
activ
sinc
angiotensin
stem
angiotensinogen
delet
angiotensinogen
diminish
stimul
angiotensin
receptor
includ
ma
circul
angiotensinogen
deriv
liver
gener
believ
addit
angiotensinogen
product
occur
brain
kidney
adipos
tissu
campbel
haben
thoma
sernia
matsusaka
et
al
although
attract
specul
angiotensinogen
contribut
local
angiotensin
product
direct
evid
tissu
angiotensin
gener
occur
independ
liver
angiotensinogen
still
lack
inde
delet
renal
angiotensinogen
unexpectedli
affect
renal
angiotensin
level
baselin
pathophysiolog
condit
matsusaka
et
al
futur
studi
address
brain
adipos
tissu
angiotensin
level
absenc
hepat
angiotensinogen
solv
issu
uijl
et
al
studi
requir
highli
sensit
angiotensin
assay
sinc
brain
angiotensin
level
particular
extrem
low
van
thiel
et
al
lombardbanek
et
al
human
circul
angiotensinogen
level
micromolar
rang
ie
close
km
reaction
renin
order
magnitud
level
circul
ang
ii
circul
liverderiv
angiotensinogen
diffus
slowli
interstiti
space
henc
contribut
tissu
angiotensin
product
eg
heart
vascular
wall
de
lannoy
et
al
upregul
angiotensinogen
level
subject
carri
allel
angiotensinogen
gene
pregnant
women
due
fact
estrogen
stimul
angiotensinogen
synthesi
schunkert
et
al
danser
et
al
result
renin
downregul
therebi
normal
angiotensin
gener
contrast
renin
upregul
occur
patient
heart
failur
particularli
treatment
diuret
ra
blocker
diminish
angiotensinogen
excess
may
result
nearcomplet
angiotensinogen
deplet
danser
et
al
klotz
et
al
deplet
tend
occur
earlier
tissu
level
rather
circul
klotz
et
al
nevertheless
invers
relationship
renin
angiotensinogen
allow
angiotensin
level
remain
intact
wide
rang
angiotensinogen
level
even
patient
angiotensinogen
level
normal
danser
et
al
klotz
et
al
interest
mice
display
angiotensinogen
level
percent
human
still
display
similar
angiotensin
level
human
due
fact
renin
level
sever
order
magnitud
higher
human
van
thiel
et
al
import
realiz
human
also
capabl
upregul
renin
level
sever
hundredfold
balcarek
et
al
therebi
compens
signific
angiotensinogen
deplet
taken
togeth
impli
suppress
angiotensin
level
blood
plasma
angiotensinogen
deplet
substanti
like
wherea
suppress
angiotensin
tissu
level
may
alreadi
occur
less
impress
angiotensinogen
reduct
current
suppress
angiotensinogen
achiev
interfer
rna
level
oligonucleotid
fig
antisens
oligonucleotid
aso
singlestrand
synthet
nucleic
acid
complementari
specif
mrna
region
watt
corey
hybrid
mrna
degrad
occur
therebi
abrog
protein
angiotensinogen
synthesi
aso
gener
consist
nucleotid
highli
unstabl
thu
chemic
modif
requir
increas
nucleas
resist
modif
may
also
help
increas
rna
affin
select
furthermor
conjug
hepatocytetarget
ligand
triantennari
nacetylgalactosamin
galnac
facilit
select
accumul
liver
therebi
increas
potenc
mullick
et
al
ren
et
al
galnac
bind
asialoglycoprotein
receptor
hepatocyt
allow
transport
releas
aso
intracellular
compart
levin
without
galnac
aso
may
also
accumul
outsid
liver
exampl
abovement
put
angiotensinogensynthes
organ
small
interf
rna
sirna
share
aso
principl
oligonucleotid
bind
target
rna
watsoncrick
base
pair
yet
sirna
doubl
strand
increas
stabil
cell
one
strand
passeng
strand
lost
wherea
strand
guid
strand
load
rnainduc
silenc
complex
risc
risc
protein
complex
allow
guid
strand
bind
complementari
rna
region
enzym
argonaut
part
risc
cleav
mrna
galnac
conjug
appli
sirna
well
case
sirna
proprotein
convertas
subtilisinkexin
type
biannual
dose
suppress
ray
et
al
true
angiotensinogen
well
might
revolution
hypertens
pharmacotherapi
particularli
patient
nonadher
earli
studi
angiotensinogen
aso
administ
intracerebroventricular
inject
brain
shr
show
modest
reduct
angiotensinogen
level
hypothalamu
pmolg
brainstem
cortex
midbrain
cerebellum
wielbo
et
al
remark
baselin
brain
angiotensinogen
level
compar
brain
region
correspond
blood
plasma
angiotensinogen
level
data
argu
angiotensinogen
express
select
brain
nuclei
favor
presenc
trap
plasma
angiotensinogen
brain
furthermor
brainstem
ang
ii
level
decreas
margin
pgg
angiotensinogen
aso
administr
gyurko
et
al
yet
blood
pressur
decreas
mm
hg
remain
difficult
link
larg
hypotens
effect
inconsist
even
absent
chang
brain
angiotensinogen
ang
ii
thu
conclud
reflect
exclus
interfer
brain
angiotensinogen
express
studi
repeat
current
select
potent
stabl
angiotensinogen
aso
recent
studi
evalu
aso
sirna
variou
rat
model
mullick
et
al
mice
ye
et
al
also
compar
galnacconjug
nonconjug
variant
mice
hepatocytespecif
angiotensinogen
defici
abolish
angiotensinogen
accumul
proxim
tubul
greatli
diminish
renal
ang
ii
level
support
concept
renal
angiotensin
gener
depend
liverderiv
angiotensinogen
roksnoer
et
al
rat
galnacconjug
unconjug
angiotensinogen
aso
suppress
circul
angiotensinogen
although
unconjug
aso
addit
suppress
renal
adipos
angiotensinogen
mrna
nevertheless
galnacconjug
aso
sirna
effect
lower
blood
pressur
shr
mullick
et
al
uijl
et
al
suggest
interfer
renal
adipos
angiotensinogen
requir
effect
also
true
lipid
nanoparticleencapsul
angiotensinogen
sirna
deliv
liver
shr
olearczyk
et
al
unexpectedli
galnacconjug
angiotensinogen
aso
also
lower
blood
pressur
shr
fed
salt
wherea
classic
ra
blocker
ineffect
model
mullick
et
al
moreov
galnacconjug
angiotensinogen
aso
induc
renal
dysfunct
reflect
reduc
creatinin
clearanc
rat
nephrectomi
unlik
nonconjug
angiotensinogen
aso
captopril
mullick
et
al
author
specul
preserv
renal
angiotensinogen
nephrectomi
model
galnacconjug
angiotensinogen
aso
might
prevent
kidney
function
deterior
fail
support
concept
determin
renal
angiotensin
level
variou
condit
renal
angiotensinogen
product
unlik
underli
effect
galnacconjug
angiotensinogen
aso
shr
fed
salt
final
unconjug
angiotensinogen
aso
slow
polycyst
kidney
diseas
variou
polycyst
kidney
diseas
mous
model
ravichandran
et
al
fitzgibbon
et
al
sinc
approach
lower
renal
hepat
angiotensinogen
express
well
angiotensinogen
serum
conclud
degre
due
interfer
renal
angiotensinogen
although
like
due
suppress
renal
ang
ii
clearli
futur
studi
combin
galnacconjug
unconjug
angiotensinogen
asosirna
togeth
renal
ang
ii
measur
variou
model
need
final
settl
issu
renal
angiotensinogen
versu
hepat
angiotensinogen
contribut
renal
angiotensin
gener
summari
angiotensinogen
aso
sirna
show
promis
result
rodent
model
hypertens
kidney
failur
longlast
effect
particularli
excit
translat
clinic
applic
administr
per
year
may
help
elimin
nonadher
yet
major
hurdl
remain
regard
safeti
eg
immun
respons
liver
toxic
nonspecif
effect
situat
ra
activ
acut
need
etc
efficaci
particularli
context
common
comorbid
heart
failur
chronic
kidney
diseas
combin
ra
blocker
contemporari
drug
discoveri
emerg
strategi
design
develop
bispecif
therapeut
bispecif
drug
either
small
molecul
peptid
target
two
independ
signal
pathway
importantli
goal
bispecif
drug
achiev
therapeut
synergi
transcend
effect
singlepathway
activ
exampl
concept
support
approv
small
molecul
sacubitrilvalsartan
heart
failur
also
demonstr
efficaci
hypertens
ruilop
et
al
mcmurray
et
al
recent
advanc
peptid
engin
employ
design
develop
novel
design
peptid
target
pgca
meem
burnett
chen
et
al
molecular
target
well
recogn
mediat
cardioren
protect
cardiovascular
diseas
via
secondmesseng
cgmp
cardiac
hormon
anp
bnp
endogen
ligand
inde
stimul
pgcacgmp
pathway
result
number
biolog
properti
includ
natriuresi
diuresi
blood
pressur
lower
inhibit
cardiomyocyt
hypertrophi
fibroblast
prolifer
brown
white
adipocyt
enhanc
energi
util
suppress
inflammatori
cytokin
cell
inhibit
aldosteron
bordicchia
et
al
et
al
kuhn
cataliotti
et
al
also
report
chronic
activ
pgca
adenovir
bnp
gene
deliveri
shr
reduc
blood
pressur
attenu
cardiac
hypertrophi
diastol
dysfunct
human
heart
failur
chronic
pgca
augment
daili
subcutan
bnp
inject
improv
cardioren
function
clinic
symptom
chen
et
al
second
separ
molecular
target
cardioren
therapeut
ma
ma
activ
mediat
antiapoptot
antiinflammatori
vasodilatori
antithrombot
antagon
action
activ
via
ligand
ang
secondmesseng
camp
santo
et
al
trask
ferrario
addit
camp
activ
downstream
pathway
activ
ang
includ
phospholipas
pathway
santo
et
al
phosphoinositid
pathway
sampaio
et
al
lopez
verrilli
et
al
savergnini
et
al
et
al
ang
axi
also
cardioren
protect
action
model
hypertens
heart
failur
mori
et
al
van
twist
et
al
therapeut
develop
ma
limit
howev
rapid
vivo
degrad
ang
iusuf
et
al
firstinclass
bispecif
design
peptid
cotarget
ma
pgca
one
peptid
entiti
recent
engin
meem
et
al
design
peptid
replac
n
terminu
ma
agonist
ang
fig
goal
creat
bispecif
drug
ie
would
possess
greater
system
renal
vasodil
natriuret
diuret
cardiac
unload
properti
compar
either
ang
bnp
alon
potenti
would
benefici
efficaci
treatment
cardiovascular
diseas
hypertens
heart
failur
recent
report
pgca
ma
activ
valid
shown
biolog
activ
vivo
potent
sustain
cardioren
action
go
beyond
ma
pgca
alon
meem
et
al
valid
stimul
receptor
vitro
shown
increas
second
messeng
pgca
ma
cell
increas
cgmp
camp
respect
demonstr
importantli
blockad
ma
attenu
hemodynam
natriuret
diuret
respons
vivo
underscor
import
activ
ma
find
first
studi
novel
uniqu
ma
activ
possess
ang
properti
henc
gener
vitro
vivo
action
repres
altern
ra
activ
togeth
pgca
target
therapeut
implic
treatment
cardiovascular
diseas
especi
diseas
state
ra
activ
play
pivot
role
ie
hypertens
heart
failur
hypertens
heart
failur
neurohumor
imbal
character
rel
np
defici
excess
ra
activ
hawkridg
et
al
macheret
et
al
treatment
drug
target
pgca
receptor
system
ma
potenti
restor
imbal
inde
studi
report
chronic
pgca
receptor
activ
human
heart
failur
associ
improv
cardioren
function
left
ventricular
function
andor
structur
overal
clinic
outcom
chen
et
al
longterm
treatment
ang
experiment
model
cardiovascular
diseas
improv
cardiac
function
mice
prevent
cardiomyocyt
hypertrophi
apoptosi
fibrosi
mori
et
al
papinska
et
al
therefor
may
improv
hemodynam
function
diuresi
natriuresi
short
term
may
wide
potenti
applic
cardiovascular
renal
metabol
diseas
chronic
use
thu
futur
studi
need
address
full
therapeut
potenti
firstinclass
peptid
concept
optim
therapi
bival
blocker
ra
profoundli
influenc
clinic
medicin
particular
ace
inhibitor
major
impact
cardiovascular
medicin
especi
treatment
heart
failur
hypertens
ischem
heart
diseas
ferrario
mullick
oparil
et
al
mani
major
evidencebas
cardiovascular
guidelin
recommend
ace
inhibitor
firstlin
therapi
least
heart
failur
hypertens
rosendorff
et
al
yanci
et
al
whelton
et
al
wright
et
al
howev
despit
enorm
therapeut
advanc
manag
condit
patient
treat
ace
inhibitor
still
increas
risk
cardiovascular
morbid
prematur
death
moukarbel
solomon
reason
multifactori
includ
fact
ideal
ace
inhibitor
yet
develop
clinic
address
part
develop
vasopeptidas
inhibitor
omapatrilat
dual
inhibitor
ace
nep
nawarska
et
al
tabrizchi
lapoint
rouleau
drug
promis
highli
effect
treatment
endotheli
dysfunct
atherosclerosi
hypertens
heart
failur
term
super
ace
inhibitor
howev
larg
clinic
trial
live
expect
omapatrilat
fail
obtain
fda
approv
result
high
incid
angioedema
also
associ
ace
inhibitor
lesser
extent
arb
arbnep
inhibitor
owen
oliph
kosti
et
al
especi
african
american
smoker
women
older
individu
patient
previou
drug
rash
reaction
season
allergi
use
immunosuppress
drug
although
exact
caus
vasopeptidas
ace
angioedema
remain
elus
evid
suggest
may
due
excess
bradykinin
format
owe
inhibit
domain
ace
et
al
ba
stone
brown
straka
et
al
accordingli
potenti
benefit
select
inhibit
ace
c
domain
primarili
inhibit
product
ang
ii
ang
time
reduc
side
effect
prevent
bradykinin
buildup
via
continu
bradykinin
degrad
intact
n
domain
seem
attract
ace
n
domain
also
regul
breakdown
peptid
includ
peptid
tetrapeptid
acsdkp
gnrh
henc
maintain
function
n
domain
prevent
accumul
peptid
peptid
may
addit
cardiovascular
protect
health
benefit
bernstein
et
al
nevertheless
even
ideal
ace
inhibitor
without
side
effect
may
suffici
treat
patient
given
multipl
counterregulatori
mechan
within
ra
allow
ang
ii
level
return
origin
statu
even
presenc
ace
inhibit
henc
need
altern
ra
blocker
like
angiotensinogen
aso
sirna
capabl
significantli
suppressingelimin
ra
activ
even
renin
upregul
simpli
remov
substrat
angiotensin
stem
approach
sirna
particular
addit
advantag
except
long
halflif
allow
applic
limit
time
per
year
thu
offer
possibl
simultan
combat
nonadher
cours
matter
debat
remain
far
one
suppress
ra
sinc
live
without
function
much
ra
blockad
yield
well
known
side
effect
observ
trial
appli
multipl
ra
blocker
time
hypotens
renal
dysfunct
hyperkalemia
optim
degre
ra
suppress
unlik
ident
patient
undoubtedli
requir
individu
therapi
word
need
signific
even
complet
ra
blockad
patient
modest
degre
ra
blockad
might
suffici
other
altern
option
would
either
combin
classic
ra
blocker
drug
interfer
hormon
system
known
involv
hypertens
upregul
socal
protect
arm
ra
aim
ra
blockad
one
specif
locat
eg
brain
firibastat
normal
brain
ra
hyperact
consequ
regul
sympathet
tone
baroreflex
function
argininevasopressin
releas
excit
new
develop
current
take
place
combin
ace
inhibitor
nep
inhibitor
increas
np
level
inhibit
breakdown
inact
fragment
theoret
constitut
second
opportun
creat
super
ace
inhibitor
safe
widespread
use
clinic
combin
arb
nep
inhibitor
alreadi
clinic
realiti
proven
superior
effect
versu
singl
ra
blockad
recombin
brainselect
apa
inhibit
current
test
clinic
pulmonari
arteri
hypertens
overweight
patient
hypertens
respect
base
concept
degrad
ang
ii
upregul
protect
ang
wherea
apa
blockad
prevent
brain
stimul
ang
iii
final
dual
maspgca
activ
shown
promis
result
anim
studi
taken
next
step
taken
togeth
possibl
improv
extend
classic
ra
blockad
rapidli
expand
eventu
result
novel
treatment
modal
superior
efficaci
diminish
side
effect
reduc
dose
frequenc
enhanc
brain
specif
andor
capac
upregul
protect
mechan
